加载中
NASDAQHealthcareMedical - Devices
最新数据
US$1.51
−US$0.02 · -1.31%
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
常规交易时段
US$1.51
−US$0.02 · -1.31%
盘中时间采用ET。市场数据可能有所延迟。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日内区间
当前US$1.51
52周区间
当前US$1.51
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
31
偏贵
情绪
52
多空交织
风险
88
极高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日内区间
当前US$1.51
52周区间
当前US$1.51
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 421.52万 USD | 305.25万 USD | 311.18万 USD | 125.69万 USD | — |
| 销货成本 | 216.52万 USD | 180.57万 USD | 168.62万 USD | 93.02万 USD | — |
| 毛利 | 205万 USD | 124.69万 USD | 142.56万 USD | 32.67万 USD | — |
| 研究与开发 | 337.13万 USD | 239.65万 USD | 167.38万 USD | 50.74万 USD | 385.39万 USD |
| 销售、一般及管理费用 | 1050.22万 USD | 888.39万 USD | 925.85万 USD | 802.67万 USD | 492.01万 USD |
| 营业费用 | 1465.81万 USD | 1189.15万 USD | 1170.88万 USD | 1292.19万 USD | 833.69万 USD |
| 利息收入 | 11.03万 USD | 10.15万 USD | 8.48万 USD | 9676 USD | 1.44万 USD |
| 利息支出 | 1.07万 USD | 6.09万 USD | 16.71万 USD | 22.35万 USD | 7539 USD |
| 折旧和摊销 | 116.38万 USD | 121.37万 USD | 121.31万 USD | 96.67万 USD | — |
| 营业利润 | −1260.81万 USD | −1064.46万 USD | −1028.32万 USD | −1259.52万 USD | −833.69万 USD |
| 净利润 | −1243.1万 USD | −1056.87万 USD | −1015.68万 USD | −1063.17万 USD | −830.61万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年12月16日 | 1:10 | — | — |
股票拆分 | 2024年1月29日 | 1:12 | — | — |
股票拆分 | 2023年2月10日 | 1:20 | — | — |
股票拆分 | 2017年4月10日 | 2,000:1 | — | — |
股票拆分 | 2016年12月28日 | 300:1 | — | — |
股票拆分 | 2016年9月16日 | 80:1 | — | — |
已生效 2025年12月16日
1:10
已生效 2024年1月29日
1:12
已生效 2023年2月10日
1:20
已生效 2017年4月10日
2,000:1
已生效 2016年12月28日
300:1
已生效 2016年9月16日
80:1
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
